News
Solera Health launches women’s health network to fill ‘critical’ gaps in healthcare
According to the company’s research, 68 per cent of women said women’s health does not get enough attention
The US healthtech company Solera Health has announced the launch of its women’s health network of digital point solutions.
The company’s new network will cover the spectrum of women’s health needs, aiming to fill “critical gaps in care to bring more access to women who need it”.
Solera’s platform provides intensive lifestyle and behavioural social interventions to impact costly chronic conditions and offer personalised solutions.
Its research found that 68 per cent of women agreed women’s health does not get enough attention with 87 per cent feeling very or extremely interested in exploring health solutions offered by the company.
“Women’s health needs extend beyond fertility and maternity, and we have purposefully built a network that spans the lifecycle of women’s unique health needs, from pelvic floor dysfunction to menopause,” said Mary Langowski, Solera Health CEO.
“Women’s health continues to be one of the most underserved segments in our healthcare system and we are excited to expand our offerings to address some of the most prevalent health disorders women are facing today.”
Solera’s women’s health network will begin with five partner solutions – Frame Fertility, Origin, Pacify, RestoreBalance and Visana – and will address women’s physical, behavioural and social needs.
The company says the solutions serve as a complement to maternal offerings to help a health plan or employer better serve the needs of all women in its population through a single contract and IT integration.
The AI and personalised matching experience developed by Solera pairs programme participants with their “best-fit programme” based on their clinical needs and personal preferences to help them get the care they need when they need it.
Langowski said: “Solera’s women’s health network is a clinically inclusive and expansive offering, addressing key women’s health needs at every age, leading to a more satisfied, productive workforce that feels empowered and supported.
“Our new suite of evidence-based women’s health programmes continues our mission of bringing the best solutions to address the diverse clinical needs of our member populations.
“We are committed to ensuring that every individual receives the personalised care needed to achieve superior outcomes at a lower cost.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Wellness4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







1 Comment